Clinical trial
An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers.
NCT02988362 is registered in ClinicalTrials.gov with HanAll BioPharma Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers.
- Lead sponsor
- HanAll BioPharma Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 14, 2016
- Completion date
- February 4, 2017
- Enrollment
- 42 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.